Joshua Patterson
Plus aucun poste en cours
Fortune : 10 155 $ au 31/03/2024
Profil
Joshua F.
Patterson served as the Executive Director & Deputy General Counsel at Ionis Pharmaceuticals, Inc. from 2006 to 2018.
Prior to that, he worked as In-House Counsel at Amylin Pharmaceuticals, Inc. from 2000 to 2006.
He then joined Akcea Therapeutics, Inc. as the Secretary & Vice President-Legal from 2018 to 2020.
Currently, he is the Chief Compliance Officer & General Counsel at Gamida Cell Ltd.
starting from 2021 until 2024.
Mr. Patterson completed his undergraduate degree at Carthage College and his graduate degree at Syracuse University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GAMIDA CELL LTD.
0,21% | 15/03/2024 | 282 096 ( 0,21% ) | 10 155 $ | 31/03/2024 |
Anciens postes connus de Joshua Patterson
| Sociétés | Poste | Fin |
|---|---|---|
| GAMIDA CELL LTD. | Compliance Officer | 26/04/2024 |
| IONIS PHARMACEUTICALS, INC. | Director/Board Member | 01/03/2018 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/09/2006 |
| AKCEA THERAPEUTICS, INC. | General Counsel | - |
Formation de Joshua Patterson
| Carthage College | Undergraduate Degree |
| Syracuse University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
